The Middle East respiratory syndrome-related coronavirus, also known as MERS-CoV, which was first reported in Saudi Arabia in 2012. MERS-CoV is a zoonotic virus, which means it is a virus that is transmitted between animals and people. Studies have shown that humans are infected through direct or indirect contact with infected dromedary camels. MERS-CoV has been identified in dromedaries in several countries in the Middle East, Africa and South Asia. The origins of the virus are not fully understood but, according to the analysis of different virus genomes, it is believed that it may have originated in bats and was transmitted to camels sometime in the distant past. At the end of November 2019, a total of 2494 laboratory-confirmed cases of Middle East respiratory syndrome (MERS), including 858 associated deaths (case-fatality rate: 34. 4%) were reported globally; the majority of these cases were reported from Saudi Arabia (2102 cases, including 780 related deaths with a case- -fatality rate of 37.1%).
MERS-CoV belongs to the genus betacoronavirus, as does the severe acute respiratory syndrome (SARS)-CoV. MERS-CoV is a positive-sense, single-stranded RNA virus with a genome that encodes the structural proteins S, envelope (E), membrane (M), and nucleocapsid (N). Like other coronaviruses, the MERS-CoV virion utilizes a large surface spike (S) glycoprotein for interaction with and entry into the target cell. The S glycoprotein consists of a globular S1 domain at the N-terminal region, followed by membrane-proximal S2 domain, a transmembrane domain, and an intracellular domain. Determinants of cellular tropism and interaction with the target cell are within the S1 domain, while mediators of membrane fusion have been identified within the S2 domain. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for the development of MERS vaccines and therapeutics.
Fig. Schematic structures of MERS-CoV S protein.
Source: Viruses 2019, 11(1), 60; https://doi.org/10.3390/v11010060
Through co-purification with the MERS-CoV S1 domain, Scientists have identified that dipeptidyl peptidase 4 (DPP4, also called CD26) functions as a cellular receptor for MERS-CoV. DPP4 does not share any sequence or structural similarities to the previously identified human coronavirus receptors, such as angiotensin-converting enzyme 2 (ACE2) for SARS-CoV. MERS-CoV S protein has an important role in viral pathogenesis, determining host tropism and entry into host cells. The S protein contains an S1 subunit at the N terminus and an S2 subunit at the C terminus. The S1 subunit is composed of the N-terminal domain (NTD) and RBD. The RBD has a key role in the mediation of binding of MERS-CoV to cells expressing the dipeptidyl peptidase 4 (DPP4) receptor, enabling the virus to enter into target cells by fusing with cell membranes through the formation of a fusion core.
Creative Diagnostics now can provide MERS-CoV antigens and antibodies. MERS-CoV antigens can be used for scientific research, detection of MERS coronavirus and preparation of neutralizing antibodies. MERS-CoV antibodies are useful for researchers interested in viral research. This products are for research use only and are not intended for therapeutic or diagnostic applications. All of our antigens and antibodies are produced using a standardized production process to ensure the highest quality and are performance guaranteed for the applications listed on the detailed datasheets.
Product List of MERS-CoV Reagents
|DAG-H10295||MERS-CoV Nucleoprotein (aa 1-413) [His]||N/A||Antigen|
|DAG-H10296||MERS-CoV Spike protein S2 (aa 726-1296) [His]||N/A||Antigen|
|DAG-H10297||MERS-CoV Spike protein (aa 383-502) [Fc]||ELISA||Antigen|
|DAG-H10298||MERS-CoV Spike protein S1 (aa 1-725) [His]||ELISA||Antigen|
|DAG-H10300||MERS-CoV Spike protein (aa 1-1297) [His]||ELISA||Antigen|
|DAGB201||MERS-CoV Spike Protein (aa 367-606) [His]||ELISA||Antigen|
|DAGA-3103||Recombinant MERS-CoV Spike Protein (a.a.18-725, EMC 2C/2012) [His]||ELISA||Antigen|
|CABT-B1950||Anti-MERS-CoV Spike Protein polyclonal antibody||WB, IHC-P, IP||Antibody|
|CABT-B1951||Anti-MERS-CoV Spike Protein (aa 1-1297) polyclonal antibody||ELISA||Antibody|
|CABT-B1952||Anti-MERS-CoV Spike Protein S2 polyclonal antibody||WB, ELISA, IHC-P, IP||Antibody|
|CABT-B1953||Anti-MERS-CoV Spike Protein S1 (Center region ) polyclonal antibody||WB, IF, IP||Antibody|
|CABT-B1954||Anti-MERS-CoV Spike Protein S1 (N-terminal) polyclonal antibody||WB, IHC, IF, IP||Antibody|
|CABT-B1955||Anti-MERS-CoV Spike Protein S1 (C-terminal) polyclonal antibody||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1956||Anti-MERS-CoV Spike Protein S2 polyclonal antibody||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1957||Anti-MERS-CoV Spike Protein (aa 1-1297) polyclonal antibody||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1958||Anti-MERS-CoV Spike Protein (aa 726-1296) monoclonal antibody, clone 13||ELISA||Antibody|
|CABT-B1959||Anti-MERS-CoV Spike Protein (aa 1-1297) monoclonal antibody, clone 834||Neut||Antibody|
|CABT-B1960||Anti-MERS-CoV Spike Protein S1 (aa 1-725) polyclonal antibody||ELISA, WB||Antibody|
|CABT-B1961||Anti-MERS-CoV Nucleoprotein monoclonal antibody, clone 21||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1963||Anti-MERS-CoV Nucleoprotein (N-terminal) polyclonal antibody||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1964||Anti-MERS-CoV Nucleoprotein (Center region) polyclonal antibody||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1965||Anti-MERS-CoV Nucleoprotein polyclonal antibody||WB, ELISA, IHC, IF, IP||Antibody|
|CABT-B1966||Anti-MERS-CoV Nucleoprotein (Center region) polyclonal antibody||WB||Antibody|
|CABT-RM313||Mouse anti-MERS-CoV S1 monoclonal antibody, clone MN2163||ELISA, IFA||Antibody|
|CABT-RM314||Mouse anti-MERS-CoV S1 monoclonal antibody, clone MN2164||ELISA, IFA||Antibody|
MERS-CoV Related Products